My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 612

    1.

    Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.

    Greenspan SL, Nelson JB, Trump DL, Resnick NM.

    Ann Intern Med. 2007 Mar 20;146(6):416-24.PMID: 17371886 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy.

    Greenspan SL, Nelson JB, Trump DL, Wagner JM, Miller ME, Perera S, Resnick NM.

    J Clin Oncol. 2008 Sep 20;26(27):4426-34.PMID: 18802155 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Summaries for patients. Preventing bone loss in men with prostate cancer.

    [No authors listed]

    Ann Intern Med. 2007 Mar 20;146(6):I72. No abstract available. PMID: 17371883 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

    Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; Denosumab HALT Prostate Cancer Study Group.

    N Engl J Med. 2009 Aug 20;361(8):745-55. Epub 2009 Aug 11.PMID: 19671656 [PubMed - indexed for MEDLINE]Related articles

    5.

    Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.

    Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM.

    J Clin Endocrinol Metab. 2005 Dec;90(12):6410-7. Epub 2005 Sep 27.PMID: 16189261 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy.

    Bruder JM, Ma JZ, Wing N, Basler J, Katselnik D.

    J Clin Densitom. 2006 Oct-Dec;9(4):431-7. Epub 2006 Sep 6.PMID: 17097529 [PubMed - indexed for MEDLINE]Related articles

    7.

    Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.

    Clin Ther. 2009 Apr;31(4):751-61.PMID: 19446148 [PubMed - indexed for MEDLINE]Related articles

    8.

    Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.

    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.

    J Bone Miner Res. 1998 Sep;13(9):1431-8.PMID: 9738515 [PubMed - indexed for MEDLINE]Related articles

    9.

    Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.

    Kawahara T, Kobayashi T, Nishizawa K, Kobori G, Mitsumori K, Ogura K.

    Hinyokika Kiyo. 2008 Apr;54(4):261-6.PMID: 18516917 [PubMed - indexed for MEDLINE]Related articles

    10.

    Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.

    Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G, Duboeuf F, Garnero P, Arlot M, Raynal C, Meunier PJ.

    J Bone Miner Res. 2006 Feb;21(2):300-6. Epub 2005 Oct 24.PMID: 16418786 [PubMed - indexed for MEDLINE]Related articles

    11.

    Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.

    Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.

    Osteoporos Int. 2006;17(5):716-23. Epub 2006 Feb 3.PMID: 16463007 [PubMed - indexed for MEDLINE]Related articles

    12.

    Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.

    Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A.

    Ann Intern Med. 2002 Dec 3;137(11):875-83.PMID: 12458987 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.

    Miller PD, Epstein S, Sedarati F, Reginster JY.

    Curr Med Res Opin. 2008 Jan;24(1):207-13.PMID: 18042311 [PubMed - indexed for MEDLINE]Related articles

    14.

    Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.

    Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ.

    J Rheumatol. 2009 Aug;36(8):1705-14. Epub 2009 Jun 1.PMID: 19487264 [PubMed - indexed for MEDLINE]Related articles

    15.

    Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.

    Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC 2nd, Kaur A, Thompson DE, Yates J, Orloff JJ.

    Aging (Milano). 2000 Feb;12(1):1-12.PMID: 10746426 [PubMed - indexed for MEDLINE]Related articles

    16.

    Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.

    Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ.

    Urology. 2004 Aug;64(2):335-40.PMID: 15302490 [PubMed - indexed for MEDLINE]Related articles

    17.

    Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

    Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N.

    J Urol. 2003 Jun;169(6):2008-12.PMID: 12771706 [PubMed - indexed for MEDLINE]Related articles

    18.

    Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

    Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R.

    N Engl J Med. 2007 Nov 15;357(20):2028-39.PMID: 18003959 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

    Kiratli BJ, Srinivas S, Perkash I, Terris MK.

    Urology. 2001 Jan;57(1):127-32.PMID: 11164157 [PubMed - indexed for MEDLINE]Related articles

    20.

    Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.

    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.

    Prostate Cancer Prostatic Dis. 2002;5(4):304-10.PMID: 12627216 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity